Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Active Surveillance of Papillary Thyroid Microcarcinoma

NCT ID: NCT02609685Sponsor: Cedars-Sinai Medical CenterLast updated: 2026-05-07

Summary

The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.

Detailed description

The incidence of thyroid cancer has more than doubled in the last 30 years in the United States, Europe, Canada, and South America. Since nearly 50% of this increase is attributable to papillary thyroid microcarcinomas (PTMC), it appears that greater detection and diagnosis of previously subclinical disease is a major factor driving this dramatic rise. The primary objective is to estimate the rate of disease progression (growth of primary tumor or development of loco-regional/distant metastases) over a 3, 5, and 10-year period in a series of PTMC patients followed with active surveillance in the United States. Patients who opt for immediate surgery can participate in a sub-study looking at quality of life and anxiety measures as compared to those patients who enroll in the active surveillance main study. Patients who enroll in active surveillance can choose to have surgery at any time that they and their treating physician feel that it is in their best interest.

Arms & interventions

  • OtherActive Surveillance

    Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.

Outcome measures

Primary

  • Rate of disease progression

    Time frame: From time of diagnosis up to10 years of follow-up

Secondary

  • Percentage of subjects that will elect surgery despite absence of clinical progression

    Time frame: From time of diagnosis up to 10 years of follow-up

  • Impact of TSH suppression on thyroid nodule growth (in cm) as measured by ultrasound

    Time frame: Five years

  • Identify the clinicopathologic features associated with disease progression in papillary thyroid microcarcinoma patients followed with active surveillance

    Time frame: Five years

  • Identify the genetic factors associated with an increased risk of disease progression

    Time frame: Five years

  • Quality of life score as measured by City of Hope Quality of Life Scale

    Time frame: Up to five years

  • Anxiety score as measured by Memorial Anxiety Scale

    Time frame: Up to five years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation. * 2.0 cm or smaller nodules by ultrasonographic criteria * Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form * Must be able to read and write English fluently to participate in the questionnaire portion of the study Exclusion Criteria: * High-grade or poorly differentiated PTC variants * Central or lateral neck lymphadenopathy suspicious for PTC * Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion) * History of radiation to neck

Study locations (1)

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Allen Ho, MD · Contact
310-423-1220Allen.Ho@cshs.org
Allen Ho, MD · Principal Investigator

References

  • Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, Mallen-St Clair J, Chen MM, Vasquez M, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZS, Braunstein GD, Sacks WL. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2022 Sep 15;8(11):1588-96. doi: 10.1001/jamaoncol.2022.3875. Online ahead of print.(PubMed)
Active Surveillance of Papillary Thyroid Microcarcinoma | Cancerify